Comprehensive molecular characterization of urothelial bladder carcinoma
Top Cited Papers
Open Access
- 29 January 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 507 (7492), 315-322
- https://doi.org/10.1038/nature12965
Abstract
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3–TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities. This paper reports integrative molecular analyses of urothelial bladder carcinoma at the DNA, RNA, and protein levels performed as part of The Cancer Genome Atlas project; recurrent mutations were found in 32 genes, including those involved in cell-cycle regulation, chromatin regulation and kinase signalling pathways; chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far. This study of 131 high-grade muscle-invasive urothelial bladder carcinomas, part of The Cancer Genome Atlas (TCGA) project, reports recurrent mutations in 32 genes, including those involved in cell-cycle regulation, chromatin regulation and kinase signalling pathways. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any common cancer studied to date. Recurrent in-frame activating FGFR3–TACC3 fusions and expression or integration of viruses associated with gene inactivation are also identified. Importantly, potential therapeutic targets are identified in 69% of the tumours.Keywords
This publication has 37 references indexed in Scilit:
- Discovery and saturation analysis of cancer genes across 21 tumour typesNature, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Oncogenic FGFR3 gene fusions in bladder cancerHuman Molecular Genetics, 2012
- Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic AnalysisClinical Cancer Research, 2012
- Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial CarcinomaPLOS ONE, 2012
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladderNature Genetics, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urotheliumUrologic Oncology: Seminars and Original Investigations, 2010